Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

NCT06735391 is registered in ClinicalTrials.gov with Shanghai JMT-Bio Inc. as lead sponsor.

NCT NCT06735391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06735391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Lead sponsor
Shanghai JMT-Bio Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
October 23, 2024
Completion date
May 30, 2029
Enrollment
516 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

harboring egfr sensitive mutations nsclc, locally advanced or metastatic non-squamous nsclc, previously untreated systematically nsclc